Shanghai Universal Biotech Co.Ltd.

Univ Biotech released its 2026 interim report, showing first-half operating revenue of 569 million yuan, up 12.6% year on year, with a net loss attributable to the parent of 11.8 million yuan, narrowing from a loss of 13.38 million yuan in the same period last year. Second-quarter revenue was 309 million yuan, up 7.2% year on year, and the net loss attributable to the parent was 3.3 million yuan, narrowing from a loss of 7.17 million yuan a year earlier. As of the end of the second quarter, the company's total assets were 2.251 billion yuan and net assets attributable to the parent were 1.934 billion yuan. The company said its customer structure has changed significantly, with industrial customers accounting for 50.41% of main business revenue, research customers 33.77%, and other customers 15.83%. During the reporting period, order volume exceeded 110,000 transactions, and the company served more than 33,000 customers in total. Centering on its two excellence strategy, the company is strengthening coordination between third-party brands and its own brands, increasing research and development investment, and advancing digital transformation.